PL3416684T3 - Sposoby leczenia lub profilaktyki miażdżycy tętnic przez podawanie inhibitora angptl3 - Google Patents

Sposoby leczenia lub profilaktyki miażdżycy tętnic przez podawanie inhibitora angptl3

Info

Publication number
PL3416684T3
PL3416684T3 PL17706945.7T PL17706945T PL3416684T3 PL 3416684 T3 PL3416684 T3 PL 3416684T3 PL 17706945 T PL17706945 T PL 17706945T PL 3416684 T3 PL3416684 T3 PL 3416684T3
Authority
PL
Poland
Prior art keywords
angptl3
administering
inhibitor
treating
methods
Prior art date
Application number
PL17706945.7T
Other languages
English (en)
Inventor
Jesper Gromada
Viktoria Gusarova
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL3416684T3 publication Critical patent/PL3416684T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17706945.7T 2016-02-17 2017-02-13 Sposoby leczenia lub profilaktyki miażdżycy tętnic przez podawanie inhibitora angptl3 PL3416684T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296110P 2016-02-17 2016-02-17
PCT/US2017/017640 WO2017142832A1 (en) 2016-02-17 2017-02-13 Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3

Publications (1)

Publication Number Publication Date
PL3416684T3 true PL3416684T3 (pl) 2023-11-06

Family

ID=58108756

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17706945.7T PL3416684T3 (pl) 2016-02-17 2017-02-13 Sposoby leczenia lub profilaktyki miażdżycy tętnic przez podawanie inhibitora angptl3

Country Status (25)

Country Link
US (3) US20170233466A1 (pl)
EP (2) EP3416684B1 (pl)
JP (3) JP7648335B2 (pl)
KR (1) KR102860143B1 (pl)
CN (1) CN108697797A (pl)
AU (1) AU2017219602C1 (pl)
CA (1) CA3014928A1 (pl)
DK (1) DK3416684T5 (pl)
EA (1) EA201891853A1 (pl)
ES (1) ES2951262T3 (pl)
FI (1) FI3416684T3 (pl)
HR (1) HRP20230992T1 (pl)
HU (1) HUE062709T2 (pl)
IL (1) IL260931B2 (pl)
LT (1) LT3416684T (pl)
MA (1) MA44234B1 (pl)
MD (1) MD3416684T2 (pl)
MX (1) MX2018009680A (pl)
PL (1) PL3416684T3 (pl)
PT (1) PT3416684T (pl)
RS (1) RS64476B1 (pl)
SI (1) SI3416684T1 (pl)
SM (1) SMT202300219T1 (pl)
WO (1) WO2017142832A1 (pl)
ZA (1) ZA201805058B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
CN109096369B (zh) * 2018-09-10 2020-07-07 云南民族大学 一种特异性检测铜离子和硫离子的多肽、化学荧光传感器及其制备方法与应用
BR112021009054A2 (pt) * 2018-11-13 2021-08-24 Lipigon Pharmaceuticals Ab Oligonucleotídeos angptl4 influenciando a regulação do metabolismo de ácido graxo
WO2020099525A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Oligonucleotides influencing the regulation of the fatty acid metabolism
WO2020099482A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
CN110596399B (zh) * 2019-08-29 2022-07-22 首都医科大学附属北京安贞医院 检测血管生成素样蛋白8含量的物质的应用
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
KR20220131935A (ko) * 2020-01-22 2022-09-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항angptl3 항체 및 이의 용도
WO2023213779A1 (en) 2022-05-02 2023-11-09 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
CN115947779B (zh) * 2022-08-10 2025-04-25 武汉安砥生物科技有限公司 针对人血管生成素样蛋白3的免疫原性肽段及其载体疫苗和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) * 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
AU781295B2 (en) 1999-02-12 2005-05-12 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PL2121751T3 (pl) * 2006-12-08 2017-07-31 Lexicon Pharmaceuticals, Inc. Przeciwciała monoklonalne przeciwko ANGPTL3
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5711671B2 (ja) 2009-02-23 2015-05-07 ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． ポリコサノールナノ粒子
US8653047B2 (en) * 2010-01-08 2014-02-18 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
EP2996706B1 (en) 2013-03-14 2019-07-31 UAB Research Foundation Apolipoprotein mimetics and uses thereof
TW202021614A (zh) * 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
CN111394355A (zh) 2013-12-24 2020-07-10 Ionis制药公司 促血管生成素样3表达的调节
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途

Also Published As

Publication number Publication date
WO2017142832A1 (en) 2017-08-24
EP4234013A2 (en) 2023-08-30
DK3416684T3 (da) 2023-07-31
JP7648335B2 (ja) 2025-03-18
MX2018009680A (es) 2018-09-10
PT3416684T (pt) 2023-07-04
IL260931B1 (en) 2024-05-01
EA201891853A1 (ru) 2019-01-31
FI3416684T3 (fi) 2023-07-31
JP2024161504A (ja) 2024-11-19
SMT202300219T1 (it) 2023-09-06
HUE062709T2 (hu) 2023-11-28
KR102860143B1 (ko) 2025-09-16
KR20180108840A (ko) 2018-10-04
RS64476B1 (sr) 2023-09-29
ES2951262T3 (es) 2023-10-19
DK3416684T5 (da) 2024-09-16
MD3416684T2 (ro) 2023-10-31
US20170233466A1 (en) 2017-08-17
AU2017219602B2 (en) 2023-10-12
JP2019509271A (ja) 2019-04-04
EP3416684A1 (en) 2018-12-26
CN108697797A (zh) 2018-10-23
EP3416684B1 (en) 2023-06-21
US20220089711A1 (en) 2022-03-24
IL260931B2 (en) 2024-09-01
IL260931A (en) 2018-09-20
US20200079841A1 (en) 2020-03-12
HRP20230992T1 (hr) 2023-12-08
JP2022177107A (ja) 2022-11-30
AU2017219602A1 (en) 2018-08-23
ZA201805058B (en) 2019-05-29
SI3416684T1 (sl) 2023-08-31
AU2017219602C1 (en) 2024-05-09
MA44234B1 (fr) 2023-10-31
LT3416684T (lt) 2023-07-25
CA3014928A1 (en) 2017-08-24
MA44234A (fr) 2018-12-26
EP4234013A3 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
IL260931A (en) Methods of treating or preventing atherosclerosis by blocking angptl3
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL260199B (en) Cancer treatment methods
IL255189A0 (en) Cancer treatment methods
PT3322731T (pt) Método de tratamento de cancro utilizando inibidor de ponto de verificação (checkpoint) imunitário; anticorpo que se liga ao recetor de morte programada-1 (pd-1) ou ligando de morte programada 1 (pd-l1)
IL252296A0 (en) Methods for treating multiple sclerosis
IL257061A (en) Inhibitors of ezh2
SG11201708034SA (en) Methods of administering glutaminase inhibitors
ZA201808258B (en) Methods of treating pancreatic cancer
IL256207B (en) Methods for treating multiple sclerosis
PL3220952T3 (pl) Sposób leczenia lub zapobiegania udarowi
IL256109A (en) Methods for the treatment or prevention of protopathy
SG11201706693QA (en) Methods of treating infertility
LT3661510T (lt) Elgesio pakitimų gydymo būdai
EP3491129A4 (en) METHODS OF TREATING OSMIDROSIS
IL262111A (en) Monovalent inhibitors of hutnfr1 interaction
ZA201906319B (en) Methods of treating depression
GB201602802D0 (en) Method of treatment
IL262916A (en) Treatment of side effects resulting from chemo-nervous disorder
EP3148523A4 (en) Method of inhibiting or treating fibrosis
ZA201903931B (en) Method of treating meat
SG11201710199PA (en) Methods of treating multiple sclerosis
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201614718D0 (en) Systems and methods for controlling overusage of playing machines
GB201511895D0 (en) Combination therapy for treating multiple sclerosis